2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Pathology, Bioinformatics, Blood Banking, Computational Biology, Treatment Considerations, Non-Biological Therapies, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Study Population, Human, Elderly, Animal Model
PAPER

3820 U2AF1-Q157R mutation drives myelodysplasia via aberrant splicing, DNA damage, and activation of p38 MAPK and TGF-β signaling

Subash Ghimire, PhD, Yue Yang, PhD2, Mohammad Abu Sayem, PhD3, Bao Le, PhD4, Avik Dutta, PhD5, Golam Mohi, PhD6
1 University of Virginia, Charlottesville, Virginia, United States
2 University of Virginia, Charlottesville, Virginia, United States
3 University of Virginia, Charlottesville, Virginia, United States
4 University of Virginia, Charlottesville, Virginia, United States
5 University of Virginia, Charlottesville, Virginia, United States
6 University of Virginia, Charlottesville, Virginia, United States

Mutations in the spliceosome genes, SF3B1, SRSF2, and U2AF1 are frequently found in myeloid malignancies, with the highest frequency observed in myelodysplastic syndromes (MDS). Somatic missense mutations in U2AF1 (S34 and Q157) have been identified in ~11% of MDS cases and are associated with adverse clinical outcomes, but how the Q157 hotspot mutation alters hematopoietic stem cell function and produces ineffective hematopoiesis remains poorly defined. 

To determine the role of the U2AF1-Q157R mutation in the pathogenesis of MDS, we generated a novel conditional U2af1Q157R/+ knock-in mouse model. Mx1-Cre-mediated expression of the heterozygous U2af1-Q157R mutant allele resulted in macrocytic anemia, with reduced RBC, hemoglobin, and hematocrit, and increased mean corpuscular volume (MCV), while white WBC and platelet counts remained unchanged. Flow cytometric analyses revealedincreased percentages of hematopoietic stem/progenitor cells (HSPC), including LSK, LT-HSC, and ST-HSC, in the bone marrow (BM) and spleens of U2af1Q157R/+ mice. Hematopoietic progenitor colony assays showed significantly decreased numbers of CFU-GM, BFU-E, and CFU-E colonies derived from the BM of U2af1Q157R/+ mice compared with WT mice, indicating that numerical HSPC expansion did not translate into productive hematopoiesis. Transplantation of BM cells from U2af1Q157R/+ mice into lethally irradiated wild-type recipients recapitulated these phenotypes, indicating that the effects of the U2af1-Q157R mutation on the hematopoietic system are cell-autonomous.

To evaluate the functional effects of the U2af1-Q157R mutation on HSPCs in vivo, we performed competitive bone marrow transplantation using WT GFP+ (control) and Mx1-Cre;U2af1Q157R/+ GFP+ mice BM cells. Recipients of Mx1-Cre;U2af1Q157R/+ GFP+ BM exhibited markedly higher percentages of GFP+ LSK and LK cells in the BM and spleens compared with recipients of control GFP+ BM. We also observed significantly increased percentages of GFP+ cells among myeloid, megakaryocytic, B-cell, and T-cell populations, demonstrating an initial competitive advantage that could promote early clonal expansion. However, secondary transplantation revealed reduced mutant contribution to differentiated myeloid, megakaryocytic, erythroid, B-cell, and T-cell populations, indicating progressive loss of long-term self-renewal and differentiation capacity.

Since the HSC self-renewal capacity was compromised in U2af1Q157R/+ mice, we evaluated cell cycle progression in U2af1Q157R/+ mice HSPC. A higher proportion of U2af1Q157R-mutant HSPCs were in the G1 phase compared to their WT counterparts, which remained predominantly in the G0 phase, indicating a loss of quiescence in the mutant cells. Furthermore, we observed elevated R-loop formation and increased DNA double-strand breaks, marked by γ-H2AX phosphorylation, in U2af1Q157R/+ LSK cells. Consistent with these findings, ATM and CHK2 phosphorylation was increased in U2af1Q157R/+ LSK cells.

We performed RNA-seq to identify alternative splicing events in HSPCs carrying the U2af1-Q157R mutation. U2af1-Q157R altered nucleotide preference at the +1 position of the 3′ splice site and produced 975 exon-skipping and 652 exon-inclusion events in mutant LSK cells. Skipping of Ezh2 exon 14 was identified in U2af1Q157R/+ mouse LSK cells as well as in two independent human U2AF1-Q157-mutant MDS cohorts. Ectopic expression of this exon 14-deleted Ezh2 isoform impaired histone methyltransferase activity. Furthermore, expressing this isoform in mouse BM progenitors reduced erythroid (BFU-E and CFU-E) colony formation.

RNA sequencing analysis identified additional genes that were aberrantly spliced in LSK cells of U2af1Q157R/+ mice and in at least one MDS patient cohort. Notably, skipping of Map3k7 exon 12 was significantly increased while inclusion of Tgfbr2 exon 2 was reduced in U2af1Q157R/+ LSK cells. Moreover, MAP3K7 and its downstream targets, p38 MAPK and MK2, were hyperactivated in the BM of U2af1Q157R/+ mice. Similarly, phospho-SMAD2 levels were elevated in BM lysates from U2af1Q157R/+ mice, indicating activation of TGF-β signaling. Notably, pharmacological inhibition of p38 MAPK or TGFBR significantly rescued these erythroid colony formation defects in U2af1Q157R/+ BM cells. Collectively, these results suggest that U2AF1-Q157R mutation impairs HSPC function and promotes myelodysplasia through aberrant splicing, DNA damage, and activation of p38 MAPK and TGF-β signaling pathways.

Subash Ghimire, PhD: No relevant conflicts of interest to declare.